Consolidated revenue for the full year ended December 31, 2025, was approximately $54.3 million, an 18% decrease from $66.1 million in the prior year. Net loss attributable to common stockholders for 2025 was approximately $11.7 million, or ($0.44) per diluted share, an improvement from a net loss of $13.4 million, or ($0.65) per diluted share, in 2024. Total operating expenses decreased by approximately $20.1 million, or 50%, to $19.9 million in 2025, largely due to a 20% decrease in salaries and wages and a 49% decrease in professional fees. The company ended 2025 with approximately $13.7 million in cash, no meaningful unsecured debt, and approximately $15.0 million in working capital. Healthcare Operations revenue decreased by $12.6 million to $39.7 million, primarily due to a decrease in prescriptions filled, partially offset by increased reimbursement rates. e-Commerce revenues increased by $0.8 million to $14.6 million, driven by higher airtime and hardware sales and favorable foreign currency impact. Overall gross margin declined to approximately 20% in 2025 from 26% in 2024, with both healthcare and e-commerce segments experiencing decreases. The company successfully cut over $2 million in annualized costs, including reducing staff headcount by more than 25% and eliminating unused office space.